Close Menu

NEW YORK – Newark, California-based biotechnology firm Rain Therapeutics on Thursday announced the closing of a $63 million Series B financing round.

The financing was led by Boxer Capital and included new investors Cormorant Asset Management, Samsara BioCapital, Janus Henderson Investors, and Logos Capital. Existing investors, including BVF Partners LP and Perceptive Advisors also participated in the round. In a statement, Rain said that Boxer Capital will appoint a representative to its board of directors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.